Revises Full-Year 2022 Guidance:
-- Full-Year 2022 Net Sales Guidance of $3.53 Billion to $3.60 Billion, Reflecting Revised Net Sales Expectations for TEPEZZA and Inflammation Segment ---- Full-Year 2022 Adjusted EBITDA Guidance of $1.30 Billion to $1.35 Billion --
-- Full-Year 2022 TEPEZZA Net Sales Percentage Growth in the High-Teens --
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.